Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Cycloprolylglycine (CPG)

Plain-language summaryIntrigue 60 / 100

Cycloprolylglycine (CPG) is a cyclic dipeptide your body produces naturally and stores in spinal fluid. It is the active metabolite of noopept; when you take noopept your body converts it to CPG, which does most of the work. Researchers study it on its own to understand brain mechanisms. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

48/100

Endogenous noopept metabolite with real probe value but thin, consortium-concentrated evidence

Look, CPG sits in an unusual position. It’s not a synthetic nootropic with an invented mechanism; it’s an endogenous cyclic dipeptide that shows up in human CSF and brain tissue, which immediately gives it biological legitimacy that most research peptides don’t have. The story here is that noopept, a compound with real but messy pharmacology, gets hydrolyzed in vivo, and what the body actually does with it is partly form CPG. So if you want to understand what noopept is actually doing at the receptor level, CPG is the probe that lets you ask that question cleanly, without the prodrug pharmacology confounding the read.

The mechanism overlaps substantially with noopept: BDNF and NGF upregulation, modulation of NMDA and AMPA receptor expression, some antioxidant activity, modest cholinergic facilitation. None of these are individually paradigm-shifting. Neurotrophin upregulation is a crowded mechanism space, and glutamate receptor modulation has been worked from every direction for decades. What’s interesting is the combination, and particularly the idea that an endogenous molecule is doing this at all. That raises a real question: is CPG part of a broader endogenous regulatory loop for synaptic plasticity? Thats a legitimate thing to want to know.

Here’s the problem though: the evidence base is thin and geographically concentrated. The foundational work comes from Voronina, Gudasheva, and collaborators at the Zakusov Institute, the same group that developed noopept. That’s not inherently disqualifying, they’re serious pharmacologists with peer-reviewed output, but independent replication of the CPG-specific findings is sparse. We’re largely in single-consortium territory, which is exactly where you have to be cautious about effect size inflation and publication bias. The rodent data is real, but the human-relevant story for CPG as a standalone is essentially absent. You can extrapolate cautiously from the noopept clinical literature, but that’s not the same thing.

What we actually like about CPG is the bench value proposition. If your lab is studying endogenous cyclic dipeptide signaling in the CNS, or running noopept mechanism work and want to separate prodrug effects from active metabolite effects, CPG is the compound you need. Thats a real use case, even if its narrow. The translational arrow is weak right now, there’s no serious human program for CPG as a standalone compound, but as a tool for investigators who already have a reason to care about this mechanism space, it earns a spot in a serious research library.

We see CPG as a legitimate niche probe with an interesting endogenous angle, modest but real mechanism, weak evidence base, and genuine utility for a small set of investigators. Don’t prioritize it unless noopept mechanism work or endogenous cyclic dipeptide biology is central to your program. If it is, it belongs on your list.

Novelty

62

Mechanism promise

58

In-category differentiation

48

Evidence quality

30

Translational signal

25

Research bench value

60

Rationale CPG earns points on novelty (endogenous CNS dipeptide recently characterized as an independent research entity) and bench probe value (isolates active-metabolite pharmacology from noopept prodrug effects), but the evidence base is heavily concentrated in the Gudasheva/Zakusov Institute group with minimal independent replication and essentially no human-specific efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous dipeptide / noopept metabolite

An endogenous dipeptide present in mammalian CSF; the principal active metabolite of noopept and a research probe for endogenous nootropic mechanisms.

Abstract

Cycloprolylglycine (CPG; cyclic Pro-Gly dipeptide) is an endogenous cyclic dipeptide identified in human cerebrospinal fluid and brain tissue. The compound is the principal active metabolite of noopept (formed by enzymatic cyclization after the parent compound’s hydrolysis) and has been investigated as an independent research probe. Pharmacology overlaps with noopept: BDNF and NGF upregulation, antioxidant effects, modulation of NMDA and AMPA receptor expression, modest cholinergic facilitation. CPG itself is sold as a research peptide for investigators studying the noopept mechanism without the parent compound’s prodrug pharmacology. Pharmacokinetics: plasma half-life ~2 hours; oral bioavailability presumed adequate. Doses are not formally established; rodent doses scale to micrograms per kilogram.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-200Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nortriptyline

Plain-language summaryIntrigue 56 / 100

Nortriptyline (Pamelor, Aventyl) is the active leftover of amitriptyline, sold separately after FDA approval in 1964. The body strips one methyl group off amitriptyline to produce nortriptyline, and that small change shifts the drug toward blocking the norepinephrine pump preferentially with much less serotonin activity. It also drops the muscarinic and antihistamine load somewhat, which makes it more tolerable than the parent compound. Among older tricyclics it has the cleanest defined therapeutic blood-level window (50 to 150 ng/mL), which means clinicians can dose it precisely with a blood test rather than guessing. Used for depression, neuropathic pain, and migraine prevention. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A well-characterized legacy TCA with real bench utility but minimal novelty and largely superseded clinical standing

Look, nortriptyline is what happens when pharmacology matures past a compound. Approved in 1964, it’s the N-desmethyl metabolite of amitriptyline, and that metabolic parentage is itself telling: the original compound was already considered a workhorse before nortriptyline entered independent clinical use. The mechanism is completely mapped. NET Ki around 4 nM, SERT closer to 18 nM, meaningful H1 antagonism, reduced but real muscarinic load. Every branch of that receptor profile has been studied to exhaustion across multiple decades in multiple labs. Thats not a criticism of the compound’s history; it just means a serious investigator isn’t going to find mechanistic surprises here.

Where nortriptyline does outperform amitriptyline is tolerability, specifically the lower anticholinergic burden (M1 Ki roughly 150 nM versus 18 nM for the parent), and that difference is real and clinically meaningful. But the comparison set matters. Against modern SNRIs like duloxetine for neuropathic pain, or against varenicline for smoking cessation, nortriptyline is second-line or lower across nearly every approved and off-label indication. It hasn’t defined its class; it refined a position within a class that’s mostly been vacated by newer chemotypes.

The evidence quality is actually one of the stronger aspects of the profile. Sixty years of clinical data, well-established therapeutic plasma monitoring windows (50 to 150 ng/mL), CYP2D6 metabolism characterized in detail, interaction profiles documented across hundreds of polypharmacy combinations. That depth of evidence is genuinely useful for some research designs and shouldn’t be dismissed. The translational signal is also real: nortriptyline works for depression, works for neuropathic pain, and the smoking cessation signal is well-replicated even if the effect size is modest against better alternatives.

What we think is most honest here: nortriptyline retains specific research value as the canonical secondary amine TCA reference compound. If you’re studying NET-preferring reuptake inhibition in a TCA scaffold, or comparing anticholinergic burden across tricyclic structures, it’s the right tool. That use case is narrow but legitimate, and it’s what keeps the bench_value score from bottoming out. But as an object of primary research interest, honestly, there isn’t much frontier left. The compound doesn’t unlock new biology, the indication space is saturated with better options, and the mechanism has no unexplored angles that the literature hasn’t already addressed multiple times. Score accordingly.

Novelty

18

Mechanism promise

22

In-category differentiation

28

Evidence quality

68

Translational signal

62

Research bench value

55

Rationale Nortriptyline scores low on novelty and mechanism because it is a 60-year-old TCA with a thoroughly mapped pharmacology; it earns back points on evidence quality and translational signal given decades of real clinical use, and modest bench_value credit as the canonical secondary amine TCA reference compound in mechanistic studies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of amitriptyline; a NET-preferring TCA with a more favorable side effect profile.

Abstract

Nortriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine; CAS 72-69-5; molecular formula C19H21N; molecular weight 263.38) is the N-desmethyl active metabolite of amitriptyline, marketed independently as Pamelor and Aventyl after FDA approval in 1964. As a secondary amine TCA, the compound exhibits substantially greater NET selectivity than amitriptyline (NET Ki approximately 4 nM, SERT Ki approximately 18 nM) and reduced muscarinic antagonism (M1 Ki approximately 150 nM versus 18 nM for amitriptyline), producing a cleaner side effect profile. H1 antagonism remains significant (Ki approximately 10 nM) and contributes to residual sedation, but the anticholinergic burden is meaningfully lower. Plasma half-life is 18 to 35 hours; metabolism is via CYP2D6 (primary). Approved for major depressive disorder; widely used at low dose (10 to 75 mg) for chronic pain, neuropathy, and as a smoking cessation aid (off-label). Therapeutic plasma concentrations are well-defined (50 to 150 ng/mL) and routinely monitored, distinguishing nortriptyline from most modern antidepressants. Used as the canonical secondary amine TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-217Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Quetiapine

Plain-language summaryIntrigue 65 / 100

Quetiapine (Seroquel) is a workhorse atypical antipsychotic from AstraZeneca, approved in 1997, that has become equally famous as an off-label sleep aid because its potent histamine-receptor blockade makes the low-dose form (25 to 100 mg) profoundly sedating. At full antipsychotic doses (300 to 800 mg) it is used for schizophrenia and acute mania. At intermediate doses (150 to 300 mg) it is FDA-approved for bipolar depression and as add-on for major depression. The active leftover after liver metabolism, norquetiapine, blocks the norepinephrine pump and contributes to the antidepressant effect. Metabolic side effects (weight gain, lipid and glucose disturbance) are real and dose-related, which has prompted concern about its widespread use as a sleep drug. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Well-evidenced atypical antipsychotic; low novelty, the norquetiapine metabolite angle is its only remaining research hook

Look, quetiapine is about as far from a frontier compound as you can get. Approved by the FDA in 1997, it’s had nearly three decades of clinical scrutiny across schizophrenia, bipolar disorder, and adjunctive MDD, and the literature is enormous. That massive evidence base is real and we’d never dispute the clinical utility. But clinical utility isn’t what this library is scoring, and on novelty and differentiation, quetiapine earns almost nothing.

The receptor profile is famously broad: 5-HT2A, H1, alpha-1, 5-HT1A partial agonism, and a D2 Ki of roughly 770 nM that makes it the weakest D2 binder in the class. That weak D2 story was actually interesting at one point, back when investigators were trying to understand why some atypicals showed fewer extrapyramidal effects. But that conversation is decades old and well-resolved. The mechanism that still earns quetiapine some research attention is the norquetiapine metabolite angle: norquetiapine is a potent NET inhibitor (Ki around 35 nM) and a 5-HT2C antagonist, which explains the compound’s antidepressant signal and its FDA approval as an MDD adjunct. Thats genuinely interesting pharmacology; a real example of a case where the metabolite carries a mechanistically distinct payload from the parent. We like that story. What we don’t like is that the story is also well-characterized at this point, with the norquetiapine mechanism essentially textbook since the early 2010s.

The translational and evidence scores are high because quetiapine simply has an exceptional clinical database. Multiple phase 3 trials across multiple indications, replicated over years, with regulatory consensus in several jurisdictions. If you want a reference atypical antipsychotic for mechanism work or as a comparison arm in a preclinical model, quetiapine is a reasonable choice. That’s real bench value and we’re crediting it. But a reference compound isn’t the same as an indispensable probe, and nothing about quetiapine’s mechanism lets you answer a question you genuinely couldn’t answer with a contemporary or successor compound.

The off-label hypnotic use, which is where most investigators encounter it outside psychiatry, is an honest embarrassment. Using a broad-spectrum atypical at 25 to 100 mg for sleep is largely an H1-mediated antihistamine effect, and the side-effect burden relative to that marginal signal is hard to defend. No serious investigator is building a sleep research program around this compound right now.

What quetiapine is, in the end, is a well-understood and clinically important drug that happens to have a metabolite worth knowing about. The norquetiapine/NET angle is genuinely interesting as a case study in active metabolite pharmacology. The compound itself as a research target scores where it scores: high on evidence, low on novelty, and not particularly differentiated in a very crowded class.

Novelty

18

Mechanism promise

38

In-category differentiation

28

Evidence quality

82

Translational signal

75

Research bench value

45

Rationale Quetiapine’s near-three-decade clinical history yields high evidence and translational scores, but novelty and differentiation are floor-level for an approved drug in a crowded antipsychotic class; the norquetiapine NET inhibitor story keeps mechanism and bench value from bottoming out but doesn’t rescue the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic

A dibenzothiazepine atypical antipsychotic with broad receptor binding; the active metabolite norquetiapine is a NET inhibitor contributing to antidepressant efficacy.

Abstract

Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol; CAS 111974-69-7; molecular formula C21H25N3O2S; molecular weight 383.51) is a dibenzothiazepine atypical antipsychotic developed at AstraZeneca and approved by the FDA in 1997 under the trade name Seroquel. The receptor profile is broad: D2 (Ki approximately 770 nM, the weakest of the antipsychotic class), 5-HT2A (Ki approximately 295 nM), H1 (Ki approximately 11 nM), alpha-1 (Ki approximately 22 nM), 5-HT1A partial agonism. The active metabolite norquetiapine (formed via CYP3A4) is a potent NET inhibitor (Ki approximately 35 nM) and a 5-HT2C antagonist, contributing to antidepressant efficacy and supporting the FDA-approved adjunctive use in major depressive disorder. Plasma half-life is 6 to 7 hours; metabolism is via CYP3A4. Approved for schizophrenia, bipolar I disorder (mania, depression, maintenance), and adjunctive in MDD. Off-label use as a hypnotic at 25 to 100 mg is widespread despite a poor efficacy-to-side-effect ratio for that indication. Used as a reference broad-spectrum atypical antipsychotic in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-233Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tandospirone

Plain-language summaryIntrigue 47 / 100

Tandospirone (Sediel, Senparen) is a Japanese-developed second-generation azapirone from Sumitomo, approved in Japan in 1996 and China in 2004. It has not been pursued in Western markets. Mechanistically it is closely related to buspirone, partially activating the serotonin 5-HT1A receptor, but with somewhat higher intrinsic activity at the receptor (around 60 percent versus buspirone’s 35 percent). Used for generalized anxiety and adjustment disorders, with some research interest in cognitive effects through 5-HT1A in the prefrontal cortex. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

A mature azapirone 5-HT1A partial agonist with narrow bench utility as a buspirone comparator

Look, tandospirone is a perfectly competent azapirone. Developed at Sumitomo, approved in Japan in 1996 and China in 2004, it does what the class does: partial agonism at 5-HT1A with a binding affinity around 27 nM and intrinsic activity in the 60 percent range. That last number is actually the most interesting thing about it. Buspirone, the dominant Western reference azapirone, sits closer to 40-45 percent intrinsic activity, so tandospirone offers a way to ask whether higher partial agonism translates to meaningfully better anxiolytic or antidepressant signal in a head-to-head experimental setup. Thats a real, answerable question.

The problem is that the question isnt very exciting anymore. 5-HT1A partial agonism has been studied relentlessly since buspirone hit the US market in 1986, and the clinical returns across the azapirone class have been modest. GAD is a genuine indication, but nothing in this receptor corner has broken out into something field-defining. Tandospirone’s clinical literature is almost entirely Japanese and Chinese, peer-reviewed but difficult to replicate in Western contexts, and the mechanistic work points back to the same receptor biology the field has understood for decades. The evidence base is real; it’s just mature.

Sourcing outside Japan and China is genuinely awkward. It’s not a Western research staple, which means the research-grade supply chain is thin compared to buspirone. We’ve seen this pattern with other Asian-market approvals where Western labs end up defaulting to the more available analog because sourcing friction outweighs the marginal mechanistic difference. The active metabolite 1-PP is also shared across azapirones, which can muddy interpretation when you’re trying to attribute effects specifically to the parent compound versus class-level pharmacology.

What we think: tandospirone has a narrow legitimate use case as a reference compound when 5-HT1A intrinsic activity gradations genuinely matter to your experimental design. If you’re constructing a dose-response curve across the partial agonism range and need something between buspirone and a full agonist, tandospirone fills that slot. But thats a specific niche, not a broad research program. The compound isn’t overhyped, it isn’t disproven, it just lives in a thoroughly mapped mechanistic corner of psychiatric pharmacology. For investigators interested in the serotonin receptor landscape from a fresh angle, the multi-target profile of something like vortioxetine or the ongoing work in 5-HT2A/1A crosstalk around psychoplastogens is where the real action is right now. Tandospirone belongs where the numbers put it: a serviceable reference tool in a class that ran out of frontier a long time ago.

Novelty

22

Mechanism promise

22

In-category differentiation

28

Evidence quality

48

Translational signal

42

Research bench value

35

Rationale Tandospirone is a 30-year-old Asian-market anxiolytic in a thoroughly characterized receptor class; its only differentiating feature is marginally higher 5-HT1A intrinsic activity than buspirone, giving it a narrow reference-tool use case but no serious novelty or mechanistic frontier value. Evidence is real but geographically concentrated and non-paradigm-shifting, placing it firmly in piracetam territory on the overall scale.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic (Asian markets)

A second-generation azapirone 5-HT1A partial agonist marketed in Japan and China; not approved in Western markets.

Abstract

Tandospirone ((1R,2R,6S,7S)-4-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]butyl})-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; CAS 87760-53-0; molecular formula C21H29N5O2; molecular weight 383.49) is a second-generation azapirone 5-HT1A partial agonist developed at Sumitomo and approved in Japan in 1996 (Sediel) and China in 2004 (Senparen). Receptor profile is closely related to buspirone: 5-HT1A affinity approximately 27 nM (intrinsic activity approximately 60 percent, higher than buspirone); minimal D2 affinity. Compared to buspirone, the higher 5-HT1A intrinsic activity is hypothesized to produce somewhat greater anxiolytic and antidepressant effect. Plasma half-life is approximately 1 hour; metabolism is via CYP3A4 with active metabolite 1-PP common to the azapirone class. Approved indications include generalized anxiety disorder and adjustment disorder with anxiety; off-label use in depression. Not approved in the US or EU. Used as a reference azapirone with higher 5-HT1A intrinsic activity than buspirone in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-249Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Andarine (S-4)

Our opinion on this compoundEstablished workhorse

26/100

Superseded prototype SARM with abandoned clinical development and narrow SAR probe utility

Yeah, andarine is historically important and practically irrelevant for most serious research programs right now. It’s the structural parent of the entire aryl propionamide SARM lineage, GTx-007, the compound Dalton’s group at the University of Tennessee used to establish the SARM concept before they handed the baton to ostarine and moved on. That lineage story is genuinely interesting. The compound itself is not.

Here’s the problem: andarine was superseded by its own derivative. Ostarine (enobosarm, GTx-024) exists specifically because S-4’s clinical development hit a wall in the form of that dose-dependent visual disturbance, the yellow-green color tint that appears around 50 mg and above. The mechanism appears to involve non-AR-mediated binding to retinal photoreceptor proteins, and while it reverses on discontinuation, it was clinically unacceptable for any chronic-use indication. GTx didnt abandon S-4 because the AR biology was wrong. They abandoned it because a structurally similar compound without the retinal liability was sitting in the pipeline. That’s not a research compound’s origin story you want to build a program around.

The SARM mechanism itself, tissue-selective AR partial agonism through the propionamide scaffold, is now mature pharmacology. The class has moved past andarine in every meaningful direction. Ostarine went to phase 3 in cancer cachexia and muscle wasting. LGD-4033 has published human PK data. RAD-140 has brain-penetrant properties that open a different set of questions entirely. Andarine is the structural ancestor of all of them, but ancestry doesn’t translate into research utility in 2026.

What we’d actually grant it: the retinal side effect is genuinely undercharacterized. The non-AR mechanism behind the photoreceptor binding is an open question, and if someone wanted to probe SARM off-target effects in visual tissue or build an in vitro assay for retinal safety screening in novel androgen modulators, S-4 is the natural tool. Thats a real research niche. The compound also has reference value in aryl propionamide SAR panels, where having the original scaffold in the comparison set makes mechanistic sense.

But those uses are narrow and specialized. The compound has thin preclinical depth outside the original Dalton program, essentially no clinical data of its own, and competes directly against ostarine in any application where you’d actually want an aryl propionamide SARM. For most research programs, andarine is a historical footnote kept in the library for completeness and lineage documentation. We dont expect it to drive a serious research agenda, and the score reflects that honestly.

Novelty

22

Mechanism promise

28

In-category differentiation

20

Evidence quality

30

Translational signal

22

Research bench value

45

Rationale Andarine scores low primarily because it was actively superseded by its own structural derivative (ostarine) and clinical development was abandoned due to retinal tolerability failure rather than mechanism failure; the aryl propionamide SARM mechanism is now decades-old pharmacology, and the compound has essentially no clinical data and limited research utility beyond SAR reference work and the undercharacterized photoreceptor side effect.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator (early-generation)

An early-generation aryl propionamide SARM; the structural lineage compound from which ostarine was derived.

Abstract

Andarine (S-4, GTx-007; CAS 401900-40-1; molecular formula C19H18F3N3O6; molecular weight 441.36) is a non-steroidal aryl propionamide SARM developed by Dalton and colleagues at the University of Tennessee, the structural precursor to ostarine. The compound exhibits tissue-selective AR agonism and demonstrated efficacy in osteoporosis and BPH preclinical models. Notable for a dose-dependent visual side effect: yellow-green tint to vision at doses above approximately 50 mg, attributed to non-AR-mediated effects on retinal photoreceptors and pigments. The visual effect is reversible on discontinuation but proved clinically unacceptable for long-term development; GTx redirected development to ostarine for superior tolerability. Andarine retains research utility as the prototype aryl propionamide SARM and is widely used recreationally despite no regulatory approval. Plasma half-life is approximately 4 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-264Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Triptorelin

Plain-language summaryIntrigue 55 / 100

Triptorelin (Trelstar) is a synthetic 10-amino-acid GnRH agonist used in long-acting depot form for prostate cancer, endometriosis, and precocious puberty. The pharmacology has a counterintuitive twist: continuous (rather than the normal pulsatile) GnRH receptor stimulation initially causes a flare in testosterone or estrogen, then desensitizes and downregulates the receptor over one to two weeks, producing sustained suppression. So a drug that activates the GnRH system ends up shutting down sex hormone production. The depot formulations release peptide over one, three, or six months. In bodybuilding circles a single-shot dose has been used (anecdotally and unwisely) as post-cycle therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature FDA-approved GnRH agonist with solid evidence but negligible novelty in a crowded class

Look, triptorelin is a competent, well-characterized clinical tool that does exactly what it says it does. The pharmacology here is about as settled as pharmacology gets: flood the pituitary GnRH receptors continuously, desensitize and downregulate them, and you get medical castration. That mechanism was worked out decades before the 2000 FDA approval of Trelstar, and theres nothing particularly surprising left to find in it. This is not a criticism of the compound as a drug. It’s a criticism of the compound as a research frontier.

The GnRH agonist class is genuinely crowded. Leuprolide has dominated the space since the 1980s and remains the reference standard in most academic endocrine pharmacology labs. Goserelin and histrelin fill the same niche. Triptorelin competes on depot formulation options and a slightly differentiated approval profile, but it isnt best-in-class on any dimension that would give a bench scientist a reason to reach for it specifically over its peers. If your question requires a GnRH agonist probe, you probably already have a protocol built around leuprolide.

What we do credit: the evidence base is real. Multiple phase 3 RCTs across prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. Well-replicated mechanism, clean PK data across depot formulations (1-month, 3-month, 6-month), and a regulatory record that spans more than two decades. The translational signal is unambiguous. This is a compound that works in humans on its stated targets. Thats worth something, even if it doesn’t generate novel research questions.

Honestly, the scenario where triptorelin earns a slot in a serious research program is fairly narrow: HPG axis suppression as a model condition for studying downstream hormone-dependent biology, testosterone flare characterization in oncology models, or comparative GnRH receptor desensitization kinetics. For those questions, its a legitimate tool. But for investigators looking for compounds that open new mechanistic territory or generate the kind of data that moves a field, triptorelin doesnt offer that. The interesting GnRH biology is increasingly happening in the GnRH antagonist space (degarelix, relugolix) and in the kisspeptin-neurokinin signaling layer upstream of the receptor. Triptorelin sits downstream of that action and well behind the frontier.

We keep it in the library as a reference-grade GnRH agonist with documented PK and a clean regulatory trail. What we don’t think is that a researcher picking this up today is likely to find something new. The territory has been mapped.

Novelty

20

Mechanism promise

28

In-category differentiation

25

Evidence quality

78

Translational signal

72

Research bench value

42

Rationale Triptorelin’s high evidence and translational scores reflect genuine regulatory validation and well-replicated clinical outcomes across four approved indications, but those gains are largely cancelled by rock-bottom novelty (1970s chemistry, mechanism textbook-complete) and weak differentiation in a class that includes leuprolide, goserelin, and histrelin. Bench value exists but is constrained by the availability of interchangeable GnRH agonist reference tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic GnRH agonist (decapeptide)

A synthetic GnRH agonist decapeptide used for paradoxical HPG suppression in prostate cancer, endometriosis, and precocious puberty.

Abstract

Triptorelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; CAS 57773-63-4; molecular formula C64H82N18O13; molecular weight 1311.45) is a synthetic GnRH (LHRH) agonist decapeptide developed in the 1970s and approved by the FDA in 2000 (Trelstar). Mechanism: continuous occupation of pituitary GnRH receptors initially produces a flare in LH, FSH, and consequent sex hormone secretion (1 to 2 weeks); chronic exposure desensitizes and downregulates GnRH receptors, producing a sustained reduction in LH and FSH and, downstream, in testosterone (men) and estradiol (women). Plasma half-life of the parent peptide is approximately 3 hours; depot formulations release peptide over 1, 3, or 6 months for sustained suppression. Approved indications include locally advanced and metastatic prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. The flare period in prostate cancer is mitigated by concurrent androgen receptor antagonist (bicalutamide). Used as a reference GnRH agonist in academic endocrine pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-282Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bromocriptine

Plain-language summaryIntrigue 58 / 100

Bromocriptine is a semi-synthetic ergot alkaloid (chemically descended from a fungus that grows on rye) that activates D2 dopamine receptors. It was the first dopamine agonist used for Parkinson disease and remains the standard treatment for prolactin-secreting pituitary tumors, where it shrinks the tumor and normalizes hormone levels. It also has off-label uses in type 2 diabetes (a quick-release morning formulation called Cycloset improves glucose control through hypothalamic dopamine signaling) and has been investigated for obesity. Long-term ergot exposure carries cardiac valve and lung scarring risk, which has shifted prescribing toward newer non-ergot alternatives like pramipexole. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature D2 agonist with an interesting circadian-metabolic angle, largely superseded in its original indications

Bromocriptine is a 1978 approval that’s had a genuinely interesting second act, but the honest read is that it’s a mature compound navigating three different indication spaces and either been supplanted or remains a minor player in each of them.

The core mechanism is D2 dopamine agonism, with secondary D1, alpha-adrenergic, and serotonergic activity. In Parkinson disease it was largely replaced by cleaner non-ergot agonists like pramipexole and ropinirole, which carry fewer fibrotic and ergot-class side effects. In prolactinoma, cabergoline has better receptor selectivity and tolerability. The original indications are not where the interesting research is.

The Cycloset story is more compelling. The circadian dopaminergic hypothesis holds that the morning dopamine peak in the SCN-hypothalamic axis sets metabolic state, and that resetting this rhythm with a timed-release D2 agonist can improve insulin sensitivity independent of weight or direct insulin-pathway intervention. That’s a genuinely different angle than every other T2D mechanism in the current pharmacopeia. The CYCLOSET Safety Trial and supporting work showed real HbA1c reductions, though effect sizes are modest compared to GLP-1 receptor agonists. What we find interesting is less the effect size and more the mechanism: it implies a neuroendocrine-metabolic interface that’s still undercharacterized, and bromocriptine is currently the only approved probe for it in a metabolic context.

The evidence base is solid in the aggregate. Decades of clinical use, FDA approval across multiple indications, and the 2009 Cycloset approval came with actual phase 3 data. Translational signal is real but not dramatic: it works, in modest ways, across multiple systems. Evidence quality and translational signal are the highest-scoring axes here, and they hold the overall up.

Where bromocriptine loses points is novelty and differentiation. Theres not much open research territory. The compound is fully characterized, the pharmacokinetics are understood, and the major clinical questions have been answered. Researchers working on dopamine receptor pharmacology still use it as a reference agonist, which gives it modest bench value, but its not shaping the questions being asked. Investigators in the circadian-metabolic space might pull it as a probe, but we’d want to see more replication of the central SCN-metabolic hypothesis before calling it a priority tool.

The overall picture: a well-documented compound with a mildly interesting metabolic angle, clear real-world effects, and limited research upside for anyone not specifically working the circadian-dopamine-metabolic axis. Not junk. Just not the frontier.

Novelty

20

Mechanism promise

40

In-category differentiation

42

Evidence quality

75

Translational signal

67

Research bench value

52

Rationale Bromocriptine scores well on evidence quality (multi-decade clinical literature, two separate FDA approvals) and translational signal, but novelty is low for a 1978 compound and differentiation is weak since it has been supplanted by cleaner agents in both Parkinson and prolactinoma. The Cycloset circadian-dopamine metabolic mechanism is the only genuinely interesting current research angle, and it elevates mechanism and bench value modestly, but not enough to move the overall meaningfully.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoline D2 dopamine receptor agonist

An ergoline-derived D2 receptor agonist; used in Parkinson disease, prolactinoma, and (off-label) for diabetes and obesity research.

Abstract

Bromocriptine (2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-alpha-(2-methylpropyl)ergotaman-3′,6′,18-trione; CAS 25614-03-3; molecular formula C32H40BrN5O5; molecular weight 654.59) is a semi-synthetic ergoline derivative developed at Sandoz and approved by the FDA in 1978 (Parlodel) for Parkinson disease and hyperprolactinemia. The compound is a high-affinity D2 dopamine receptor agonist (Ki approximately 5 nM) with secondary D1, alpha-adrenergic, and serotonergic effects. The dopaminergic activity in pituitary lactotrophs suppresses prolactin secretion (the prolactinoma indication); the activity in basal ganglia provides modest symptomatic relief in Parkinson disease (largely supplanted by levodopa and non-ergot agonists). A formulation released in the morning (Cycloset, FDA approved 2009) is approved for type 2 diabetes; the rationale is reset of the circadian dopaminergic peak and consequent metabolic improvement. Plasma half-life is 4 to 6 hours; metabolism is hepatic via CYP3A4. Used as a reference D2 agonist with broad receptor profile.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-315Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cutamesine (SA-4503)

Our opinion on this compoundNiche research probe

54/100

Cleanest sigma-1 probe available; real bench utility but modest and mixed clinical results keep the ceiling low

Look, sigma-1 is genuinely interesting biology. It’s not a traditional receptor. It’s a chaperone protein sitting at the mitochondria-associated ER membrane, regulating IP3 receptors, calcium transfer between organelles, and cellular stress responses. When a compound engages sigma-1, you’re not turning a GPCR on or off. You’re modulating a protein that helps the cell manage ER stress and mitochondrial calcium homeostasis. Thats a different kind of pharmacology, and it opens angles that conventional receptor agonism doesn’t reach.

SA-4503 is the cleanest tool you can buy for studying that biology. Ki of roughly 17 nM at sigma-1 with greater than 100-fold selectivity over sigma-2, and minimal off-target binding beyond that. Most sigma-1 ligands are messy. Fluvoxamine hits sigma-1 but it’s primarily an SSRI, so you can’t attribute any effect cleanly. PRE-084 has been used in academic labs but SA-4503 has become the canonical reference compound precisely because the selectivity story is tight. If your hypothesis is sigma-1 mediated, this is the compound you need to run it cleanly.

Here’s the thing: the clinical picture muddies the enthusiasm considerably. The phase 2 ischemic stroke trial (60 mg, starting within 72 hours, 28 days) showed modest improvement. The MDD phase 2 results were mixed. We don’t see the kind of signal here that makes an investigator want to restructure a research program around the target. Sigma-1’s role in neuroprotection has generated decades of preclinical work and the bench-to-clinic arrow is weaker than the mechanistic story implies. That gap is real and honestly we don’t have a clean explanation for it yet.

What keeps the score from dropping further is exactly that bench utility. Sigma-1 has been pulled into COVID-19 biology (the virus binds sigma-1 through the ORF9c protein), neurodegeneration, addiction circuits, and pain processing. If you’re running any of those programs and you want a clean pharmacological probe to dissect sigma-1 contribution, SA-4503 is irreplaceable. It’s not that the compound is exciting in the way that a novel triple agonist or a mitochondrial peptide is exciting. It’s that for a specific class of research questions, its the only rigorous tool.

We think this lands firmly in niche-probe territory. Dont buy it unless sigma-1 is already in your hypothesis. If it is, dont buy anything else.

Novelty

40

Mechanism promise

60

In-category differentiation

68

Evidence quality

50

Translational signal

38

Research bench value

72

Rationale SA-4503 scores primarily on differentiation and bench value: it’s the canonical selective sigma-1 agonist and nothing else comes close on selectivity, which matters if you’re running a sigma-1 program. But the sigma-1 story is decades old, phase 2 results in both stroke and MDD were modest to mixed, and the indication space is specialized enough that most investigators won’t touch it unless sigma-1 is already in their hypothesis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sigma-1 receptor agonist

A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

Abstract

Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-332Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tramadol

Plain-language summaryIntrigue 56 / 100

Tramadol, sold as Ultram, is an atypical opioid analgesic that combines weak direct mu-opioid receptor binding with serotonin and norepinephrine reuptake inhibition (the SNRI mechanism shared with antidepressants). The opioid effect comes mostly from a metabolite called M1, generated by the CYP2D6 liver enzyme, which means CYP2D6 ultra-rapid metabolizers (about 7 percent of Caucasians, higher in some other populations) get dramatic opioid effects from standard doses. The dual mechanism creates two distinct hazards: opioid dependence and serotonin syndrome when combined with SSRIs or other serotonergic drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature atypical opioid fully characterized; canonical reference compound with no active frontier research angle

Look, tramadol is about as thoroughly characterized as a drug gets. Developed at Grunenthal in the 1970s, FDA approved in 1995 as Ultram, and then rescheduled to Schedule IV in 2014 after accumulating abuse data. The dual mechanism (weak mu-opioid receptor agonism plus serotonin-norepinephrine reuptake inhibition) was genuinely interesting when first described. Thats not 2026.

The pharmacology is textbook at this point. The parent compound has modest mu-opioid affinity (Ki around 2 microM), and the real opioid activity comes from CYP2D6-mediated conversion to O-desmethyltramadol (M1), which sits roughly 200-fold higher in receptor affinity. The SNRI component contributes to the analgesic profile but also creates the serotonin syndrome risk that makes combination use genuinely dangerous. SERT Ki around 1 microM, NET Ki around 0.4 microM. None of this is contested. None of it is novel. It’s the kind of mechanism that gets a single textbook paragraph and stays there.

Where tramadol does earn its keep is as a reference compound for specific mechanistic work. CYP2D6 pharmacogenomics researchers use it as a clean model for prodrug activation studies, given how neatly M1 formation maps to metabolizer phenotype. Serotonin syndrome risk modeling uses tramadol as a canonical dual-mechanism case when probing drug-drug interaction space. That’s real value, and we credit it. But it’s narrow, and those aren’t frontier questions.

The evidence base is actually quite solid relative to a lot of what’s in the library. Decades of clinical PK/PD data, well-replicated across diverse populations, good pharmacogenomic characterization of poor versus ultrarapid CYP2D6 metabolizer outcomes. Evidence quality isn’t the limiting factor here. The issue is that all that evidence has already answered the questions it was built to answer.

We don’t see an emerging research angle that would push tramadol back onto a serious investigator’s priority list. It’s not being repurposed for a novel indication with real momentum. It’s not a sharper probe than alternatives for the opioid questions that actually matter right now, things like OPRM1 allosterism, biased agonism at the mu receptor, or opioid-sparing combination mechanisms. The Schedule IV status adds real regulatory friction without any corresponding research upside. If you’re building a program around pain pharmacology, there are cleaner tools for every question tramadol can address. It sits in the library primarily as a reference standard for dual-mechanism analgesic work, and that’s about the ceiling.

Novelty

20

Mechanism promise

30

In-category differentiation

40

Evidence quality

75

Translational signal

70

Research bench value

45

Rationale Evidence quality and translational signal are high (approved drug, decades of replicated clinical PK/PD data), but novelty and mechanism interest are low: 1970s compound, completely characterized pharmacology, no emerging repurposing signal. Bench value is modest but real as a CYP2D6 prodrug model and serotonin syndrome reference case, insufficient to substantially elevate the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical opioid (mu-opioid + SNRI)

A weak mu-opioid agonist with serotonin-norepinephrine reuptake inhibition; an atypical analgesic with abuse and serotonin syndrome risk.

Abstract

Tramadol ((1R,2R)-rel-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol; CAS 27203-92-5; molecular formula C16H25NO2; molecular weight 263.38) is an atypical opioid analgesic developed at Grunenthal in the 1970s and approved by the FDA in 1995 (Ultram). The compound is a weak mu-opioid receptor agonist (Ki approximately 2 microM, low affinity); the active metabolite O-desmethyltramadol (M1, formed via CYP2D6) has approximately 200-fold higher mu-opioid affinity. Distinct from pure opioids by additional serotonin and norepinephrine reuptake inhibition (SERT Ki approximately 1 microM, NET Ki approximately 0.4 microM), contributing to the analgesic profile and to serotonin syndrome risk when combined with other serotonergic drugs. Plasma half-life is approximately 6 hours; metabolism is via CYP2D6 (M1 production) and CYP3A4. Schedule IV in the US since 2014. The combined opioid and SNRI activity produces seizures (rare at therapeutic doses, more common in overdose), serotonin syndrome (with concurrent serotonergic drugs), and abuse potential intermediate between non-opioid analgesics and full opioids. Used as the canonical atypical opioid in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-348Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Darbepoetin alfa

Plain-language summaryIntrigue 54 / 100

Darbepoetin alfa, sold as Aranesp, is Amgen’s hyperglycosylated EPO analog with two extra sugar chains added to the protein backbone. The added glycosylation extends the plasma half-life from hours to days, supporting once-weekly or once-every-three-weeks dosing instead of three-times-weekly EPO. Mechanism and safety profile are otherwise identical to native EPO, including the same cardiovascular concerns at high doses. Approved in 2001, it is widely used in dialysis units and oncology infusion centers. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

An approved 25-year-old EPO analog with solid PK innovation but minimal research novelty

Look, darbepoetin alfa is exactly what the abstract says it is: native EPO with two extra N-linked glycan chains at positions 30 and 88. That glycoengineering was genuinely impressive when the Amgen team was working it out in the late 1990s, and it produced a drug (Aranesp) that cleared FDA approval in 2001. But thats 25 years ago. The mechanism is JAK2/STAT5 via the EPO receptor, which is about as well-understood as erythropoiesis biology gets, and the pharmacological innovation here is entirely pharmacokinetic, not biological. Half-life runs roughly 25 hours subcutaneous versus 6-13 hours for native EPO; receptor binding affinity is actually about 4-fold lower than epoetin alfa at equimolar doses. You’re not getting new biology. You’re getting a longer dosing window on old biology.

The clinical evidence is solid, and we’ll credit it. Large replicated RCTs support the approved CKD and chemotherapy-induced anemia indications. But the TREAT trial (Pfeffer et al., 2009, NEJM) landed hard: targeting higher hemoglobin in CKD diabetic patients with darbepoetin didn’t improve cardiovascular or renal outcomes and was associated with increased stroke risk. That trial cooled a lot of enthusiasm for ESA optimization and illustrates the ceiling here. The compound works for what it was designed for. Whether that translates to research merit for Kodiac’s library is a different question, and on that axis it’s weaker.

What we like: darbepoetin is the canonical long-acting EPO analog. If you’re running erythropoiesis studies requiring prolonged receptor signaling without serial injections, it’s the obvious tool. There’s also legitimate research interest in non-hematopoietic EPO receptor biology, particularly neuroprotective and cardioprotective signaling arms, where a long-acting form has real probe utility. But the EPOR neuroprotection story has circulated for two decades without decisive human translation, and darbepoetin isn’t the reason for that stall.

The class itself, long-acting ESAs, isn’t a frontier anyone is racing toward right now. The genuinely interesting EPO-adjacent work is in HIF-prolyl hydroxylase inhibitors like roxadustat and daprodustat, which hit the oxygen-sensing pathway upstream and carry a far more novel mechanism. Darbepoetin doesn’t compete there. Its score reflects a compound that performs reliably in its approved niche, but “reliable and approved” is precisely what this rubric is designed NOT to reward.

Novelty

25

Mechanism promise

22

In-category differentiation

45

Evidence quality

75

Translational signal

65

Research bench value

50

Rationale Darbepoetin’s score is held down by low novelty (25-year-old approved drug mechanistically identical to native EPO) and unremarkable biology despite strong clinical evidence; the glycoengineering story is real but the science is now textbook. Its only meaningful edge is as the canonical long-acting EPO tool, though the class has been outpaced by upstream HIF-PH inhibitors for frontier research.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting EPO analog

A hyperglycosylated EPO analog with two additional N-linked glycan chains; extended plasma half-life for less frequent dosing.

Abstract

Darbepoetin alfa (CAS 209810-58-2; modified EPO with two additional N-linked glycosylation sites at amino acid positions 30 and 88; molecular weight approximately 37 kDa) is a hyperglycosylated EPO analog developed at Amgen and approved by the FDA in 2001 (Aranesp). The compound has the same EPO receptor binding mechanism as native EPO but with substantially extended plasma half-life (approximately 25 hours subcutaneous, versus 6 to 13 hours for native EPO) owing to the additional carbohydrate chains slowing renal and hepatic clearance. The receptor binding affinity is approximately 4-fold lower than native EPO at equimolar doses, but the longer half-life produces greater erythropoietic effect per dose. Approved indications match native EPO (CKD anemia, chemotherapy-induced anemia). Used as the canonical long-acting EPO analog in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-364Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 45 46 47 48 49 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.